title: A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome.
abstract: OBJECTIVE
  The effects of exogenous melatonin on sleep, daytime sleepiness, fatigue, and alertness were investigated in 22 patients with delayed sleep phase syndrome whose nocturnal sleep was restricted to the interval from 24:00 to 08:00 hours. This study was a randomized, double-blind, placebo-controlled crossover trial. Subjects received either placebo or melatonin (5 mg) daily for 4 weeks, underwent a 1-week washout period, and then were given the other treatment for an additional 4 weeks. Patients could take the melatonin between 19:00 and 21:00 hours, which allowed them to select the time they felt to be most beneficial for the phase-setting effects of the medication.
  
  
  METHODS
  Two consecutive overnight polysomnographic recordings were performed on three occasions: at baseline (before treatment), after 4 weeks of melatonin treatment, and after 4 weeks of placebo treatment.
  
  
  RESULTS
  In the 20 patients who completed the study, sleep onset latency was significantly reduced while subjects were taking melatonin as compared with both placebo and baseline. There was no evidence that melatonin altered total sleep time (as compared with baseline total sleep time), but there was a significant decrease in total sleep time while patients were taking placebo. Melatonin did not result in altered scores on subjective measures of sleepiness, fatigue, and alertness, which were administered at different times of the day. After an imposed conventional sleep period (from 24:00 to 08:00), subjects taking melatonin reported being less sleepy and fatigued than they did while taking placebo.
  
  
  CONCLUSIONS
  Melatonin ameliorated some symptoms of delayed sleep phase syndrome, as confirmed by both objective and subjective measures. No adverse effects of melatonin were noted during the 4-week treatment period.
authors.affiliation: Department of Psychiatry, University of Toronto, and University Health Network, Toronto Western Hospital, Ontario, Canada. lkayumov@playfair.utoronto.ca
authors.forename: L
authors.initials: L
authors.lastname: Kayumov
authors.forename: G
authors.initials: G
authors.lastname: Brown
authors.forename: R
authors.initials: R
authors.lastname: Jindal
authors.forename: K
authors.initials: K
authors.lastname: Buttoo
authors.forename: C M
authors.initials: CM
authors.lastname: Shapiro
mesh_terms: D000328:Adult; D002491:Central Nervous System Agents / Q000008:administration & dosage* / Q000652:urine; D019454:Chronotherapy; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008550:Melatonin / Q000008:administration & dosage* / Q000652:urine; D008875:Middle Aged; D017286:Polysomnography; D012890:Sleep / Q000187:drug effects*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D002491:Central Nervous System Agents; D008550:Melatonin